Analytical methods
Direct sequencing of genomic exonic DNA, including flanking intronic sequences. Reverse transcriptase PCR analysis of mRNA extracted from cultured skin fibroblasts or hair roots for deep intronic mutations causing RNA splicing aberrations (X-linked form). Multiplex ligation-dependent probe amplification (MLPA) for detection of submicroscopic deletions and duplications. Conventional cytogenetic analysis for detection of structural chromosome rearrangements. Next-generation sequencing is a promising new technique for a genetic heterogenous disorder like Alport syndrome.
Analytical validation
Confirmation in an independent biological sample from the index case or an affected relative. Single exon deletions and duplications should be confirmed with another technique.
Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence)
The most widely used estimate of the prevalence of Alport syndrome is 1:5000, based on the finding of about 300 cases in Utah and southern Idaho in a population of 1 500 000 people. 1 The incidence of Alport syndrome was found to be 1:53 000 in Finland, 2 and 1:17 000 in southern Sweden. 3 The inheritance is X-linked in B85% of the families, autosomal recessive in B15%, and autosomal dominant in very few families.
1.9 If applicable, prevalence in the ethnic group of the investigated person Not applicable.
Diagnostic setting
Comment: Mutation analysis is mainly used for confirmation of a clinical diagnosis and in relation to genetic counselling. Prenatal diagnosis and pre-implantation genetic diagnosis are available for families with a known mutation. In families with the X-linked form of
the disease, prenatal diagnosis is performed only after sex determination, when the foetus is male. 
TEST CHARACTERISTICS

Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases, a general statement should be given even if quantification can only be made on a case-by-case basis.
X-linked form: highly dependent on fulfillment of the clinical criteria for Alport syndrome 4 and may be supported by immunohistochemical findings in a kidney and/or skin biopsy. Above 80% in families fulfilling three or more diagnostic criteria. Higher in families with obvious X-linked inheritance, and higher in males than in females. 5 Autosomal recessive form: highly dependent on fulfilment of the clinical criteria for Alport syndrome 4 and may be supported by abnormal immunohistochemical findings in a kidney biopsy, and normal immunohistochemical findings in a skin biopsy. Above 80% in families fulfilling three or more diagnostic criteria. Higher in families with consanguinity, and in patients with a family history of thin basement membrane disease/benign familial hematuria.
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases, a general statement should be given even if quantification can only be made on a case-by-case basis.
X-linked form: almost 100% in males by the age of 20 years. Autosomal recessive form: approaches 100% in males and females by the age of 20 years.
Positive clinical predictive value (life-time risk to develop the disease if the test is positive)
X-linked form: almost 100% with respect to end-stage renal disease (ESRD) in males, and 30-40% in females.
Autosomal recessive form: almost 100% for patients with homozygous or compound heterozygous COL4A3/COL4A4 mutations. Heterozygotes can have a completely normal phenotype, or a broad spectrum of symptoms ranging from thin basement membrane disease/benign familial hematuria (OMIM #141200) to ESRD.
Negative clinical predictive value (Probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.
Index case in that family had been tested: X-linked form: almost 100%. Autosomal recessive form: almost 100% for patients with homozygous or compound heterozygous COL4A3/COL4A4 mutations. Heterozygotes can have a completely normal phenotype, or a broad spectrum of symptoms ranging from thin basement membrane disease/benign familial hematuria (OMIM #141200) to ESRD.
Index case in that family had not been tested: X-linked form: unknown, but probably high. Autosomal recessive form: unknown, but probably high. 4. MLPA analysis of genomic DNA for COL4A5 deletion/ duplication. 6 3.1.2 Describe the burden of alternative diagnostic methods to the patient. Kidney biopsy confers a risk to the patient (bleeding, infection, and pain), and a skin biopsy will result in a tiny scar.
How is the cost effectiveness of alternative diagnostic methods to be judged?
Genetic testing is useful for confirming a clinical diagnosis, informing genetic counselling, and facilitating prenatal diagnosis and preimplantation genetic diagnosis. The three type-IV collagen genes, COL4A5, COL4A3, and COL4A4, are very large genes with 48-53 exons and a coding sequence of 45000 bp. New technologies such as next generation sequencing may lower costs and turn-around time.
Will disease management be influenced by the result of a genetic test?
3.2 Predictive Setting: The tested person is clinically unaffected but carries an increased risk based on family history (To be answered if in 1.10 'B' was marked)
Will the result of a genetic test influence lifestyle and prevention?
If the test result is positive (please describe): If the test is positive, clinical follow-up and genetic counselling should be recommended. Careful management of blood pressure in a patient with a positive predictive test prolongs the functioning life of a patient's native kidneys and postpones the need for renal replacement therapy.
If the test result is negative (please describe):
Clinical follow-up is not relevant if the test is negative for a known familial mutation.
3.2.2 Which options in view of lifestyle and prevention does a person at-risk have if no genetic test has been done (please describe)? Avoiding potentially nephrotoxic drugs, and the same interdisciplinary surveillance programme comprising nephrological/pediatric, ophthalmological, and audiological examination as for those with a positive genetic test. The frequency depends on the clinical findings.
3.3 Genetic risk assessment in family members of a diseased person (To be answered if in 1.10 'C' was marked) 3.3.1 Does the result of a genetic test resolve the genetic situation in that family? Yes. The risk assessment depends on the mode of inheritance; X-linked, autosomal recessive or dominant.
Can a genetic test in the index patient save genetic or other tests in family members?
Yes. If a pathogenic mutation has been identified in the index patient, genetic counselling and testing for the familial mutation could be offered to relatives at risk. If a relative tests negative, then none of their offspring are at risk and they will not need to be tested.
Does a positive genetic test result in the index patient enable a predictive test in a family member?
Yes. Carrier testing and pre-symptomatic testing in relatives will be possible. 
Prenatal diagnosis
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe) Genetic testing can be useful for the patient/family in relation to genetic counselling. Genetic testing of relatives can also be relevant in relation to selection of potential family donors for kidney transplantation. Nonsense mutations, frame shifts and larger structural rearrangements) are associated with a younger age at ESRD as compared with missense mutations. The first group of mutations confer on an affected male patient a probability of of 90% of developing ESRD before the age of 30 years. The risk is 50% for patients with a missense mutation. 7 Deletions in the adjacent 5'-end of both COL4A5 and the neighbouring COL4A6 gene are associated with Alport syndrome with diffuse leiomyomatosis (OMIM #308940).
The AMME complex (Alport syndrome, mental retardation, midface hypoplasia, and elliptocytosis; OMIM #300194) is a contigious gene deletion syndrome which includes deletion of COL4A5 together with neighbouring genes.
Management (please describe)
Interdisciplinary clinical follow-up at renal/pediatric, audiological and ophthalmological clinics. Genetic counselling. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers may reduce proteinuria and slow the progression of the disease, although the effect need to be confirmed in randomized, clinical trials.
